Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease, characterized by impaired wound repair, tissue remodeling and fibrosis. Immune system may participate in the development and progression of the disease as indicated by altered activity in IPF sufferers. This study investigates t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1436491/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555670949691392 |
|---|---|
| author | Agata Maciejewska Piotr Czernia Magdalena Piotrowska-Mieczkowska Beata Wajda Bartosz Słomiński Jan Romantowski Adam Sudoł Małgorzata Dąbrowska Lucyna Górska Tomasz Smiatacz Marek Niedoszytko Ewa Jassem Maria Skrzypkowska Piotr Trzonkowski |
| author_facet | Agata Maciejewska Piotr Czernia Magdalena Piotrowska-Mieczkowska Beata Wajda Bartosz Słomiński Jan Romantowski Adam Sudoł Małgorzata Dąbrowska Lucyna Górska Tomasz Smiatacz Marek Niedoszytko Ewa Jassem Maria Skrzypkowska Piotr Trzonkowski |
| author_sort | Agata Maciejewska |
| collection | DOAJ |
| description | Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease, characterized by impaired wound repair, tissue remodeling and fibrosis. Immune system may participate in the development and progression of the disease as indicated by altered activity in IPF sufferers. This study investigates the immune response to the BNT162b2 COVID-19 vaccine in patients with IPF compared to healthy controls, with a particular focus on evaluation of antibody responses, interferon-gamma release, cytokine profiling and a broad panel of immune cell subpopulations. IPF patients without prior exposure to SARS-CoV-2 had undetectable levels of anti-N IgG antibodies, highlighting their lack of previous infection. After vaccination, IPF patients showed a significant increase in anti-S1 IgG and IgA antibodies, though their levels were lower compared to healthy controls and convalescent IPF patients. Additionally, IPF patients exhibited altered proportions of regulatory T cells (Tregs) and effector T lymphocytes (Teffs) before and after vaccination. Specifically, IPF patients had higher percentages of Tregs with a Th2 phenotype and Th17 Tregs, along with reduced proportions of Th1/17 Tregs. Teffs in IPF patients showed a decrease in Th1-like and Th2-like populations after vaccination. Moreover, IPF patients demonstrated elevated populations of cytotoxic T lymphocytes (Tc) before vaccination and increased levels of γδ Tc cells throughout the study. Alterations in cytokine profiles were also observed, IPF patients showed higher levels of IL-6 and IL-22 compared to healthy controls. These findings suggest a distinct immune response in IPF patients to the COVID-19 vaccine, characterized by differences in antibody production, T cell differentiation and cytokine secretion compared to healthy individuals. |
| format | Article |
| id | doaj-art-4b5bb69c0fa24ef5acd429a6b04ac7fd |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-4b5bb69c0fa24ef5acd429a6b04ac7fd2025-01-08T05:10:24ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14364911436491Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patientsAgata Maciejewska0Piotr Czernia1Magdalena Piotrowska-Mieczkowska2Beata Wajda3Bartosz Słomiński4Jan Romantowski5Adam Sudoł6Małgorzata Dąbrowska7Lucyna Górska8Tomasz Smiatacz9Marek Niedoszytko10Ewa Jassem11Maria Skrzypkowska12Piotr Trzonkowski13Department of Medical Immunology, Medical University of Gdansk, Gdansk, PolandDepartment of Pneumonology, Medical University of Gdansk, Gdansk, PolandDepartment of Medical Immunology, Medical University of Gdansk, Gdansk, PolandDepartment of Pneumonology, Medical University of Gdansk, Gdansk, PolandDepartment of Medical Immunology, Medical University of Gdansk, Gdansk, PolandDepartment of Allergology, Medical University of Gdansk, Gdansk, PolandCentral Clinical Laboratory, University Clinical Centre, Gdansk, PolandCentral Clinical Laboratory, University Clinical Centre, Gdansk, PolandDepartment of Allergology, Medical University of Gdansk, Gdansk, PolandDepartment of Infectious Diseases, Medical University of Gdansk, Gdansk, PolandDepartment of Allergology, Medical University of Gdansk, Gdansk, PolandDepartment of Pneumonology, Medical University of Gdansk, Gdansk, PolandDepartment of Medical Immunology, Medical University of Gdansk, Gdansk, PolandDepartment of Medical Immunology, Medical University of Gdansk, Gdansk, PolandIdiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease, characterized by impaired wound repair, tissue remodeling and fibrosis. Immune system may participate in the development and progression of the disease as indicated by altered activity in IPF sufferers. This study investigates the immune response to the BNT162b2 COVID-19 vaccine in patients with IPF compared to healthy controls, with a particular focus on evaluation of antibody responses, interferon-gamma release, cytokine profiling and a broad panel of immune cell subpopulations. IPF patients without prior exposure to SARS-CoV-2 had undetectable levels of anti-N IgG antibodies, highlighting their lack of previous infection. After vaccination, IPF patients showed a significant increase in anti-S1 IgG and IgA antibodies, though their levels were lower compared to healthy controls and convalescent IPF patients. Additionally, IPF patients exhibited altered proportions of regulatory T cells (Tregs) and effector T lymphocytes (Teffs) before and after vaccination. Specifically, IPF patients had higher percentages of Tregs with a Th2 phenotype and Th17 Tregs, along with reduced proportions of Th1/17 Tregs. Teffs in IPF patients showed a decrease in Th1-like and Th2-like populations after vaccination. Moreover, IPF patients demonstrated elevated populations of cytotoxic T lymphocytes (Tc) before vaccination and increased levels of γδ Tc cells throughout the study. Alterations in cytokine profiles were also observed, IPF patients showed higher levels of IL-6 and IL-22 compared to healthy controls. These findings suggest a distinct immune response in IPF patients to the COVID-19 vaccine, characterized by differences in antibody production, T cell differentiation and cytokine secretion compared to healthy individuals.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1436491/fullIPFidiopathic pulmonary fibrosisphenotypeflow cytometryantibodiescytokines |
| spellingShingle | Agata Maciejewska Piotr Czernia Magdalena Piotrowska-Mieczkowska Beata Wajda Bartosz Słomiński Jan Romantowski Adam Sudoł Małgorzata Dąbrowska Lucyna Górska Tomasz Smiatacz Marek Niedoszytko Ewa Jassem Maria Skrzypkowska Piotr Trzonkowski Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients Frontiers in Immunology IPF idiopathic pulmonary fibrosis phenotype flow cytometry antibodies cytokines |
| title | Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients |
| title_full | Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients |
| title_fullStr | Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients |
| title_full_unstemmed | Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients |
| title_short | Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients |
| title_sort | comprehensive analyses of immune activity in covid 19 vaccinated idiopathic pulmonary fibrosis patients |
| topic | IPF idiopathic pulmonary fibrosis phenotype flow cytometry antibodies cytokines |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1436491/full |
| work_keys_str_mv | AT agatamaciejewska comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT piotrczernia comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT magdalenapiotrowskamieczkowska comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT beatawajda comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT bartoszsłominski comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT janromantowski comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT adamsudoł comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT małgorzatadabrowska comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT lucynagorska comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT tomaszsmiatacz comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT marekniedoszytko comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT ewajassem comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT mariaskrzypkowska comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients AT piotrtrzonkowski comprehensiveanalysesofimmuneactivityincovid19vaccinatedidiopathicpulmonaryfibrosispatients |